1 Min Read
Nov 21 (Reuters) - Janssen-Cilag International NV:
* Says submission of type II variation application to European Medicines Agency, for immunotherapy Darzalex Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.